Nektar Seeking New Partner For Exubera As Pfizer Returns Rights
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer pays Nektar $135 million, resolving Exubera contract, and returns rights – providing Nektar finds a partner, firm tells “The Pink Sheet” DAILY.
You may also be interested in...
Does MannKind Finally Have What It Takes To Get Afrezza Inhaled Insulin Cleared By FDA?
Among other things, new FDA review will test whether the company has proven that data with an old device can be applied to the new inhaler the company plans to market. MannKind is not expecting an advisory committee meeting.
An Unfortunate Step for MannKind As Its Stock Plunges Over Partnership Uncertainty
Some analysts see more market opportunity for the company's inhaled Phase I GLP-1 drug than the Afresa insulin inhaler.
An Unfortunate Step for MannKind As Its Stock Plunges Over Partnership Uncertainty
Some analysts see more market opportunity for the company's inhaled Phase I GLP-1 drug than the Afresa insulin inhaler.